6,13-Dichlorotricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-ol | 913979-31-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 二苯并环庚烯
• 英文名称: 6,13-Dichlorotricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-ol
• CAS: 913979-31-4
• 化学式: C₁₅H₁₂Cl₂O
• 分子量: 279.166
• InChiKey: QHYKAQJNVFZGII-UHFFFAOYSA-N

物化性质

• 沸点：
  416.3±45.0 °C(Predicted)
• 密度：
  1.363±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  18
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  6,13-Dichlorotricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-ol 在 lithium aluminium tetrahydride 、 sodium hydride 、 potassium carbonate 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 乙醚 、 二氯甲烷 、 乙腈 为溶剂， 反应 48.0h， 生成
  参考文献：
  名称：

  Structure-activity studies on benzhydrol-containing nipecotic acid and guvacine derivatives as potent, orally-active inhibitors of GABA uptake

  摘要：

  The introduction of lipophilic groups onto the ring nitrogen of nipecotic acid and guvacine, two known GABA uptake inhibitors, afforded potent, orally-active anticonvulsant drugs. A series of compounds is reported which explores the structure-activity relationships (SAR) in this series. Among the areas explored: side-chain SAR (aromatic-, heterocyclic-, and tricyclic-containing side chains) and modifications to the tetrahydropyridine ring. The benzhydrol ether-containing side chains afforded the most potent compounds with several exhibiting in vitro IC50 values for GABA uptake of <1 muM (including 5, Table 1; 37, 43, Table IV; and 44, Table V). Compound 44 was selected for extensive evaluation and subsequently progressed to Phase 1 clinical trials with severe adverse effects seen after single dose administration to humans.

  DOI：

  10.1021/jm00100a032
• 作为产物：
  描述：

  3-氯苄溴 在 sodium tetrahydroborate 、 三氯化铝 、 dilithium tetrachlorocuprate 、 magnesium 作用下， 以 二硫化碳 、 异丙醇 为溶剂， 反应 35.25h， 生成 6,13-Dichlorotricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-ol
  参考文献：
  名称：

  Structure-activity studies on benzhydrol-containing nipecotic acid and guvacine derivatives as potent, orally-active inhibitors of GABA uptake

  摘要：

  The introduction of lipophilic groups onto the ring nitrogen of nipecotic acid and guvacine, two known GABA uptake inhibitors, afforded potent, orally-active anticonvulsant drugs. A series of compounds is reported which explores the structure-activity relationships (SAR) in this series. Among the areas explored: side-chain SAR (aromatic-, heterocyclic-, and tricyclic-containing side chains) and modifications to the tetrahydropyridine ring. The benzhydrol ether-containing side chains afforded the most potent compounds with several exhibiting in vitro IC50 values for GABA uptake of <1 muM (including 5, Table 1; 37, 43, Table IV; and 44, Table V). Compound 44 was selected for extensive evaluation and subsequently progressed to Phase 1 clinical trials with severe adverse effects seen after single dose administration to humans.

  DOI：

  10.1021/jm00100a032

文献信息

• SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG
  申请人：Takahashi Chika

  公开号：US20130197219A1

  公开（公告）日：2013-08-01

  The present invention provides a compound having antiviral effects, particularly having growth inhibitory activity on influenza viruses, a preferred example of the compound being a substituted 3-hydroxy-4-pyridone derivative prodrug having cap-dependent endonuclease inhibitory activity.

  本发明提供了一种具有抗病毒效果的化合物，特别是对流感病毒具有生长抑制活性，该化合物的首选例子是一种具有依赖帽端核酸酶抑制活性的取代3-羟基-4-吡啶酮衍生物前药。
• SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE
  申请人：Shionogi & Co., Ltd.

  公开号：EP2444400A1

  公开（公告）日：2012-04-25

  This invention provides compounds having antiviral activities especially inhibiting activity for influenza virus, more preferably provides substituted 3-hydroxy-4-pyridone derivatives having cap-dependent endonuclease inhibitory activity.

  本发明提供了具有抗病毒活性，特别是对流感病毒有抑制活性的化合物，更优选提供了具有帽依赖性内切酶抑制活性的取代 3-羟基-4-吡啶酮衍生物。
• Substituted polycyclic carbamoyl pyridone derivative prodrug
  申请人：Shionogi & Co., Ltd.

  公开号：US10202379B2

  公开（公告）日：2019-02-12

  The present invention provides a compound having antiviral effects, particularly having growth inhibitory activity on influenza viruses, a preferred example of the compound being a substituted 3-hydroxy-4-pyridone derivative prodrug having cap-dependent endonuclease inhibitory activity.

  本发明提供了一种具有抗病毒作用，特别是对流感病毒具有生长抑制活性的化合物，该化合物的一个优选实例是具有帽依赖性内切酶抑制活性的取代 3-羟基-4-吡啶酮衍生物原药。
• [EN] DIPEPTIDYL PEPTIDASE-IV INHIBITORS<br/>[FR] INHIBITEURS DE LA DIPEPTIDYL PEPTIDASE IV
  申请人：ALANTOS PHARMACEUTICALS INC

  公开号：WO2006116157A3

  公开（公告）日：2007-04-19
• DIPEPTIDYL PEPTIDASE-IV INHIBITORS
  申请人：Kroth Heiko

  公开号：US20100009961A1

  公开（公告）日：2010-01-14

  The present invention relates generally to pyrrolidine and thiazolidine DPP-IV inhibitor compounds. The present invention also provides synthetic methods for preparation of such compounds, methods of inhibiting DPP-IV using such compounds and pharmaceutical formulations containing them for treatment of DPP-IV mediated diseases, in particular, Type-2 diabetes.